Can embryo stem cells avoid graft rejection?
Tags: EMBRYONIC stem cells; GRAFT rejection; CELL transplantation; DONATION of organs, tissues, etc.; IMMUNOLOGY
Related Articles
- Transgenic Expression of P1A Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis. Chi-Shan Li; Chong Chen; Pan Zheng; Yang Liu // PLoS ONE;2010, Vol. 5 Issue 10, p1
P1A is the first known tumor rejection antigen. It is expressed in embryonic stem cells and multiple tumors but is silent in adult tissues except for the testis and placenta. Therefore, P1A represents a prototype for onco-fetal antigens. To test the potential function of P1A in tumorigenesis, we...
- A brief history of cross-species organ transplantation. Cooper, David K. C. // Baylor University Medical Center Proceedings;Jan2012, Vol. 25 Issue 1, p49
Cross-species transplantation (xenotransplantation) offers the prospect of an unlimited supply of organs and cells for clinical transplantation, thus resolving the critical shortage of human tissues that currently prohibits a majority of patients on the waiting list from receiving transplants....
- Influence of Graft Characteristics on the Outcome of Kidney Transplantation. Soulillou, Jean-Paul; Giral, Magali // New England Journal of Medicine;5/11/2006, Vol. 354 Issue 19, p2060
The article discusses the many factors involved in chronic allograft dysfunction of kidney transplantation. The authors cite a medical study published in "The New England Journal of Medicine" that concerns newly identified donor factors that help to better determine the long term outcomes for...
- Payment of egg donors in stem cell research in the USA. Klitzman, Robert; Sauer, Mark V. // Reproductive BioMedicine Online;May2009, Vol. 18 Issue 5, p603
Arguments have been put forth as to whether women who donate oocytes for human embryonic stem cell (HESC) research should be compensated, but data regarding this issue have been scant. Recently in the United States, several States have begun funding HESC research, and patient recruitment efforts...
- An approach to the ethical donation of human embryos for harvest of stem cells. Schwartz, Philip H.; Rae, Scott B. // Reproductive BioMedicine Online;Jun2006, Vol. 12 Issue 6, p771
This paper considers embryo grading within a given infertility treatment and suggests an ethical approach to embryo donation for embryonic stem cell harvest. It is concluded that ethical considerations regarding human embryos do not necessarily preclude the use of certain embryos for biomedical...
- Attitudes of patients, healthcare professionals and ethicists towards embryonic stem cell research and donation of gametes and embryos in Germany. Krones, T.; Neuwohner, E.; Bock, K.; Manolopoulos, K.; Tinneberg, H. R.; Richter, G. // Reproductive BioMedicine Online;Nov2006, Vol. 13 Issue 5, p607
Due to the Embryo Protection Act, creation of supernumerary embryos, as well as egg and embryo donation, is prohibited in Germany. Human stem cell research is regulated through the Act on stem cells that came into force in 2002. A cross-sectional survey of 101 IVF couples (n = 202) in two...
- Beyond the 'embryo question': human embryonic stem cell ethics in the context of biomaterial donation in the UK. Bahadur, G.; Morrison, M.; Machin, L. // Reproductive BioMedicine Online;Dec2010, Vol. 21 Issue 7, p868
Discussion about the ethics of human embryonic stem cell (ESC) research in the UK tends to be dominated by the divisive and potentially intractable issue of the moral status of the embryo. This can have the effect of silencing or marginalizing other concerns, especially in the context of public...
- Embryonic death and the creation of human embryonic stem cells. Landry, Donald W.; Zucker, Howard A. // Journal of Clinical Investigation;Nov2004, Vol. 114 Issue 9, p1184
The creation of human embryonic stem cells through the destruction of a human embryo pits the value of a potential therapeutic tool against that of an early human life. This contest of values has resulted in a polarized debate that neglects areas of common interest and perspective. We suggest...
- Plerixafor 'just in time' for stem cell mobilization in a normal donor. Schriber, J.; Fauble, V.; Sproat, L. O.; Briggs, A. // Bone Marrow Transplantation;Jul2011, Vol. 46 Issue 7, p1026
A letter to the editor is presented regarding the use of plerixafor in the mobilization of stem cells for transplantation using the so-called just in time rescue strategy on a 56-year-old normal donor.
